Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial

2020 ◽  
Vol 108 (1) ◽  
pp. 150-156
Author(s):  
Gishan Ratnayake ◽  
Simone Reinwald ◽  
Mark Shackleton ◽  
Maggie Moore ◽  
Mark Voskoboynik ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radiation Therapy ◽  
Metastatic Melanoma ◽  
Phase 1 ◽  
Long Term Results ◽  
Stereotactic Radiation Therapy ◽  
Stereotactic Radiation ◽  
Phase 1 Clinical Trial

A Phase 1 Clinical Trial of Ipilimumab, Nivolumab and Radiation Therapy for Patients with Metastatic Melanoma

2018 ◽  
Vol 102 (3) ◽  
pp. S78-S79
Author(s):  
C.A. Barker ◽  
M.A. Postow ◽  
D.A. Goldman ◽  
K.S. Panageas ◽  
D. Halpenny ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Radiation Therapy ◽  
Metastatic Melanoma ◽  
Phase 1 ◽  
Phase 1 Clinical Trial

Long-Term Outcomes for Nonacoustic Schwannomas Treated with Stereotactic Radiation Therapy

2019 ◽  
Author(s):  
Anna Bistline ◽  
Andrew Song ◽  
James Evans ◽  
Christopher Farrell ◽  
David Andrews ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Radiation Therapy ◽  
Long Term Outcomes ◽  
Stereotactic Radiation

scholarly journals A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2308-2316 ◽  
Author(s):  
David H. McDermott ◽  
Qian Liu ◽  
Daniel Velez ◽  
Lizbeeth Lopez ◽  
Sandra Anaya-O’Brien ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Low Dose ◽  
Phase 1 ◽  
Cxcr4 Antagonist ◽  
Phase 1 Clinical Trial ◽  
Dose Treatment ◽  
Whim Syndrome ◽  
Key Points

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

Sign in / Sign up

Export Citation Format

Share Document